Peptides for diagnostic and therapeutic methods for celiac sprue
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsChaitan Khosla, Jiang Xia, Matthew John Siegel
Life of this patent
Estimating the term…
Abstract
Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.
Claims31
A purified oligopeptide of from about 14 amino acids in length to about 33 amino acids in length, comprising the epitope sequence (SEQ ID NO:43) PQPEKPYPQ.
An HLA-binding peptide inhibitor;
- wherein said inhibitor is an analog of an immunogenic gluten oligopeptide of at least about 8 residues in length, wherein the immunogenic gluten oligopeptide is altered by the replacement of one or more amino acids;
- and wherein said analog binds tightly to HLA molecules;
- is proteolytically stable;
- and does not activate disease-specific T cells.
A method of treating Celiac Sprue and/or dermatitis herpetiformis, the method comprising:
- administering to a patient an effective dose of an HLA-binding peptide inhibitor;
- wherein said HLA-binding peptide inhibitor attenuates gluten toxicity in said patient.
A formulation for use in treatment of Celiac Sprue and/or dermatitis herpetiformis, comprising:
- an effective dose of an HLA-binding peptide inhibitor and a pharmaceutically acceptable excipient.
Use of an HLA-binding peptide inhibitor in the treatment of HLA-DQ2 positive individuals who are either pre-disposed to type I diabetes or have developed symptoms of type I diabetes.
Dependencies are inferred from the claim text.